Primary Job Title Scientific Founder Primary Organization 
Opsonix
Gender Male
Michael Super is a Scientific Founder of Opsonix. He is a Senior Staff Scientist and a Lead of the Advanced Technology Team in the Biomimetic Microsystems Platform at the Wyss Institute for Biologically Inspired Engineering at Harvard University. At the Wyss Institute, Dr. Super is Co-Principal Investigator with Dr. Donald Ingber on a DARPA funded
project for the dialysis-like treatment of sepsis, which form the basis for Opsonix’s pathogen extracting therapy.
For more than three decades, Dr. Super has conducted preeminent research in pathogen-binding opsonins of the innate immune system. He published the first manuscripts identifying one of these opsonins as the newly described mannan-binding protein (now named mannose binding lectin / MBL), showed that the deficiency of this serum lectin caused clinical disease and frequent unexplained infections and described the molecular basis of the defect. He continued with post-doctoral work on MBL and other C-type lectins at Harvard Medical School and Boston Children’s Hospital.
Dr. Super’s R&D roles in industry included Director of Protein Biochemistry at Lexigen Pharmaceuticals, Director of Immunobiology at EMD Lexigen and Head of Hybridoma Antibody Technologies at EMD Serono. While in industry, he was responsible for preclinical development and Phase 1 through Phase 3 manufacturing of therapeutic monoclonal antibodies and immune-cytokines for cancer treatment including, huKS-IL2, hu14.18-IL2 and EMD 72000, a follower of Erbitux.
Dr. Super has authored 35 publications and over 20 patents. He received his B.Sc. from Manchester Polytechnic Metropolitan University and his M.Sc. and Ph.D. from the University of London.
